Since epidemiological studies indicate that more than 80% of infections with HIV are acquired at mucosal surfaces, a safe and effective vaccine must have the properties to stimulate both the mucosal and systemic immune responses. Infection with poliovirus results in the stimulation of both humoral and cell mediated components of the systemic immune systems. During the last funding period, we developed recombinant poliovirus genomes, termed replicons, in which the capsid gene has been substituted with HIV/SIV genes. A complementation system to provide capsid proteins in trans has been developed to encapsidate replicons. Immunization of mice or primates with encapsidated replicons results in an immune response against the target HIV/SIV protein. The goal of the proposed experiments is to further optimize the expression of HIV proteins, and enhance the immunogenicity of the replicons.
The Specific Aims are:
Specific Aim 1 : To optimize the expression of HIV envelope from poliovirus replicons. To do this, we will modify the HIV Env gene to encode different secretory translocation (signal sequences). Modifications of the replicon vector will be made to allow increased expression of HIV Env.
Specific Aim 2 : To enhance infectivity of encapsidated replicons. To enhance interactions with the target cell, replicons will be tested that contain the B subunit of cholera toxin (CTB) conjugated to the capsid, or the capsid modified to express a cell surface integrin binding motif (RGD). Based on previous studies, we will confirm that replicons formulated into liposome-cochleates can circumvent receptor mediated infection. We will determine if the modified replicons show enhanced infection and expression of foreign proteins in primary cultures of macrophages of dendritic cells.
Specific Aim 3 : To test replicon formulations for the ability to induce immune responses. The modified replicons described in Aims 1 and 2 will be tested for immunogenicity in transgenic mice that contain the receptor poliovirus. Replicons encoding cytokines will be evaluated for enhancement of the immunogenicity. The optimized formulation will be evaluated in primates with Drs. Fultz (Project 3) and Letvin (Project 4). Studies conducted during the last funding period have established the feasibility of using replicons as vaccine vectors. The experiments designed to optimize the expression of HIV/SIV proteins and enhance immunogenicity are essential for the complete evaluation of vaccine strategies required for future clinical trials.

Project Start
1999-05-01
Project End
2000-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
11
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Mestecky, Jiri; Wright, Peter F; Lopalco, Lucia et al. (2011) Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 27:469-86
Wahl, Sharon M; Redford, Maryann; Christensen, Shawna et al. (2011) Systemic and mucosal differences in HIV burden, immune, and therapeutic responses. J Acquir Immune Defic Syndr 56:401-11
Raska, Milan; Takahashi, Kazuo; Czernekova, Lydie et al. (2010) Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285:20860-9
Quan, Fu-Shi; Sailaja, Gangadhara; Skountzou, Ioanna et al. (2007) Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine 25:3841-50
Reeves, R Keith; Fultz, Patricia N (2007) Disparate effects of acute and chronic infection with SIVmac239 or SHIV-89.6P on macaque plasmacytoid dendritic cells. Virology 365:356-68
Wang, Bao-Zhong; Liu, Weimin; Kang, Sang-Moo et al. (2007) Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol 81:10869-78
Liao, Hua-Xin; Sutherland, Laura L; Xia, Shi-Mao et al. (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268-82
Gao, Feng; Korber, Bette T; Weaver, Eric et al. (2004) Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 3:S161-8
Fultz, Patricia N; Stallworth, Jackie; Porter, Donna et al. (2003) Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease. Virology 315:425-37